FOR COVID-19: Invitrogen Reagents: SuperScript III One Step Hi Fi and Superase IN

This notice is a combined synopsis/solicitation for commercial items using Simplified Acquisition Procedures. This acquisition will be made in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 12.6 - Streamlined Procedures for Evaluation and solicitation for commercial Items, as applicable, and as supplemented with additional information included in this notice. This announcement constitutes the only solicitation (a written solicitation will not be issued) and quotes are being requested. The Solicitation number is RFQ-NIAID-2080526 and the solicitation is issued as a Request for Quotes (RFQ). This acquisition will be processed under FAR Part 13 Simplified Acquisition Procedures (SAP). The solicitation documents and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2021-06, Effective 07/12/2021. The North American Industry Classification System (NAICS) code for this procurement is 325413, In-Vitro Diagnostic Substance Manufacturing, with a small business size standard size of 1,250 employees. This requirement is not set-aside for small business. This has a BRAND-NAME and a BRAND-NAME or equal requirement. This is for COVID-19 Research. Background and description of requirement: Project Background The Vaccine Research Center at the National Institutes of Health develops vaccines and monoclonal antibody therapies for the treatment of infectious diseases. The Yeast Engineering Technology & Immunobiology (YETI) Core evaluates immune responses, performs antibody discovery and engineers antibodies and immunogens against COVID-19. YETI provide a high-throughput droplet-based single cell overlap extension RT-PCR using a well-established protocol that requires the use of Superscript III One Step Hi Fi enzyme and Superase IN RNA inhibitor. Brand-name requirement, manufacturer, Invitrogen, no alternates accepted: Item: Catalog #12574035, SuperScript III One Step HiFi, 100 rxn QTY 100 Brand-name or equal requirement, manufacturer, Invitrogen, if an alternate offered item, must include the specifications for side-by-side comparison of alternate and requested product. Item: Catalog #AM2696, Superase IN, 10,000 u QTY 50 All quotes must list Country of manufacture and shipping cost per delivery (if applicable). Place of Delivery: NIAID/VRC, 40 Convent Dr, Bethesda, MD 20892 Delivery Date: This is a multiple delivery order, delivery dates between award date of PO for I year. Some deliveries before January 01, 2021 and some deliveries after January 01, 2021. Please quote according to possible delivery dates. The price must be guaranteed. *Include your DUNS number on quote *Include response to FAR 52.204-26 attachment and return with quote *Include response to FAR 52.204-24 if applicable The government intends to award a firm fixed price purchase order to the responsible contractor as a result of this RFQ that will include the terms and conditions set forth herein. The purchase order award will be based on the lowest price technically acceptable. The following FAR provisions apply to this acquisition: FAR 52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (Oct 2020) FAR 52.204-26 Covered Telecommunications Equipment or Services-Representation (Oct 2020) FAR 52.211-6 Brand-Name or Equal (Aug 1999) FAR 52.212-1 Instructions to Offerors Commercial Items (Jul 2020) FAR 52.212-3 Offerors Representations and Certifications - Commercial Items (Feb 2021) Offerors must complete annual representations and certifications on-line at http://www.sam.gov/ in accordance with FAR 52.212-3 Offerors Representations and Certifications- Commercial Items (Please ensure 52.209-2 -- Prohibition on Contracting with Inverted Domestic Corporations--Representation. (Nov 2015) is updated in your SAM record) FAR 52.203-18 Prohibition on Contracting with Entities that Require Certain Internal Confidentiality Agreements - Representation (Jan 2017) The following FAR contract clauses apply to this acquisition: FAR 52-212-4 Contract Terms and Conditions Commercial Items (Oct 2018) FAR 52-212-5 Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items (Jul 2021) FAR 52.203-19 Prohibition on Contracting with Entities that Require Certain Internal Confidentiality Agreements (Jan 2017) FAR 52.204-25 Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment (Aug 2020) FAR 52.232-40 Providing Accelerated Payments to Small Business Subcontractors (Dec 2013) FAR 52.204-19 Incorporation by Reference of Representations and Certifications (Dec 2014) HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (Dec 2015) By submission of an offer, the offeror acknowledges the requirement that a prospective awardee shall be registered in the System for Award Management (SAM) database prior to award, during performance, and through final payment of any contract, basic agreement, basic ordering agreement, or blanket purchasing agreement resulting from this solicitation (www.sam.gov). Copies of the above-referenced provisions and clauses are available from http://www.acquisition.gov & http: //www.hhs.gov/regulation/index.html or, upon request, either by telephone or fax. Offers may be mailed, e-mailed, or faxed to Ms. Skye Duffner, (E-Mail/ contact@example.gov +1 (555) 000-0000). Late submissions shall be treated in accordance with the solicitation provision at FAR 52.212-1(f) (Jun 2020) All responsible sources may submit an offer that will be considered by this Agency. Any questions or concerns regarding this solicitation should be forwarded in writing via e-mail to Ms. Skye Duffner at contact@example.gov.